Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
3.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
4.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575192
5.
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates.
Cancer Drug Resist
; 6(1): 45-58, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37065870
6.
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Cancer Treat Res Commun
; 37: 100772, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995519
7.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
J Clin Oncol
; 41(2): 198-205, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332179
8.
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Onkologie
; 35(12): 776-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23207624
9.
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.
Cancers (Basel)
; 15(1)2022 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36612047
10.
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ther Adv Med Oncol
; 14: 17588359221139601, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36479470
11.
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Cancer Res
; 82(24): 4670-4679, 2022 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222720
12.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(4): 573-584, 2021 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33480963
13.
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Expert Rev Anticancer Ther
; 20(9): 731-741, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862744
14.
Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer.
BMJ Case Rep
; 13(8)2020 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32843422
15.
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial.
Cancers (Basel)
; 12(12)2020 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33255658
16.
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.
Cancers (Basel)
; 12(3)2020 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32183023
17.
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Clin Cancer Res
; 26(22): 5820-5829, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32938620
18.
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.
Ther Adv Med Oncol
; 11: 1758835919833867, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31205497
19.
Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.
Breast Care (Basel)
; 13(4): 251-262, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30319327
20.
HER2-positive breast cancer: Current and new therapeutic strategies.
Breast
; 39: 80-88, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29631097